Janssen’s commitment
Janssen have been working tirelessly to improve the way Crohn’s is managed
Janssen has helped to improve health around the world for 75 years. More recently, Janssen has built up an extensive presence, and network of relationships, within the EMEA region (Europe, Middle East and Africa) to specifically support progress in immunology.. 1
- Activities in >100 countries 1
- Research and development investments of >€1.5 billion annually 1
In 1998, Janssen became pioneers within IBD with the introduction of the first anti-tumour necrosis factor (TNF). 2
Building on this experience and an increased understanding of disease pathophysiology, Janssen continues to lead the way and has expanded its research focus to include other targets now known to drive inflammation and autoimmune processes. 3
Working together with partners in academia and biotechnology, Janssen is committed to developing new, tailored therapeutic options in order to provide the right treatment for the right person in every part of the world. 1
Help us to complete our goal for all patients with Crohn’s disease:
References:
- Janssen. Janssen in Immunology. Available at:http://www.janssen.com/sites/www_janssen_com_emea/files/janssen_in_immunology_leaflet_for_eular_v1_11.05.15.pdf. Last accessed September 2016.
- Janssen. Gastroenterology: Leading the way to a cure by redefining the treatment paradigm. Available at: http://www.janssen.com/immunology/gastroenterology. Last accessed September 2016.
- Janssen. Discovery: Embracing new ideas to build a promising pipeline for the future. Available at: http://www.janssen.com/immunology/treatment-discovery. Last accessed September 2016.
